Interestingly, the antiproliferative effects of PPARγ ligands are stronger in TNBC cells compared to ERα-positive breast cancer cells [105], addressing that PPARγ agonists could be a good therapeutic tool for the management of the more aggressive breast cancer subtypes. This evidence concerns the gene PPARG and breast carcinoma.